| Dr Jason A Nitche, MD | |
|
457 Jack Martin Blvd, Brick, NJ 08724-7776 | |
| (732) 840-7500 | |
| (732) 840-2088 |
| Full Name | Dr Jason A Nitche |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 21 Years |
| Location | 457 Jack Martin Blvd, Brick, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700050978 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 25MA07774800 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ocean Medical Center | Brick, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthonj Llc | 6800225178 | 276 |
News Archive
Lustgarten Foundation and Stand Up To Cancer, strategic partners in the Pancreatic Cancer Collective, offer comments on research published today in the journal Nature Medicine which describes a new therapeutic approach with promise for patients with pancreatic cancer.
A study led by scientists at the Institute for Research in Biomedicine and published in Nature Communications proposes chaperone protein Hps70 as an attractive therapeutic target for the treatment of Kennedy's disease—a rare neuromuscular condition—and of castration-resistant prostate cancer.
A new study from researchers at Johns Hopkins Bloomberg School of Public Health and colleagues suggests a slowdown in the use of convalescent plasma to treat hospitalized COVID-19 patients led to a higher COVID-19 mortality during a critical period during this past winter's surge.
Obesity and obstructive sleep apnea (OSA) tend to co-exist and are associated with a variety of cardiovascular risk factors, including inflammation, insulin resistance, abnormal cholesterol, and high blood pressure. While effective therapies are available for OSA, researchers are still unclear about what interventions are most effective in reducing the burden of risk factors for cardiovascular disease associated with OSA in obese patients.
Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs such as ibuprofen and naproxen.
› Verified 2 days ago
| Entity Name | Rothman Orthopaedics Of New Jersey, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215978630 PECOS PAC ID: 6709864846 Enrollment ID: O20040713001385 |
News Archive
Lustgarten Foundation and Stand Up To Cancer, strategic partners in the Pancreatic Cancer Collective, offer comments on research published today in the journal Nature Medicine which describes a new therapeutic approach with promise for patients with pancreatic cancer.
A study led by scientists at the Institute for Research in Biomedicine and published in Nature Communications proposes chaperone protein Hps70 as an attractive therapeutic target for the treatment of Kennedy's disease—a rare neuromuscular condition—and of castration-resistant prostate cancer.
A new study from researchers at Johns Hopkins Bloomberg School of Public Health and colleagues suggests a slowdown in the use of convalescent plasma to treat hospitalized COVID-19 patients led to a higher COVID-19 mortality during a critical period during this past winter's surge.
Obesity and obstructive sleep apnea (OSA) tend to co-exist and are associated with a variety of cardiovascular risk factors, including inflammation, insulin resistance, abnormal cholesterol, and high blood pressure. While effective therapies are available for OSA, researchers are still unclear about what interventions are most effective in reducing the burden of risk factors for cardiovascular disease associated with OSA in obese patients.
Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs such as ibuprofen and naproxen.
› Verified 2 days ago
| Entity Name | Orthonj Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720557432 PECOS PAC ID: 6800225178 Enrollment ID: O20200408000333 |
News Archive
Lustgarten Foundation and Stand Up To Cancer, strategic partners in the Pancreatic Cancer Collective, offer comments on research published today in the journal Nature Medicine which describes a new therapeutic approach with promise for patients with pancreatic cancer.
A study led by scientists at the Institute for Research in Biomedicine and published in Nature Communications proposes chaperone protein Hps70 as an attractive therapeutic target for the treatment of Kennedy's disease—a rare neuromuscular condition—and of castration-resistant prostate cancer.
A new study from researchers at Johns Hopkins Bloomberg School of Public Health and colleagues suggests a slowdown in the use of convalescent plasma to treat hospitalized COVID-19 patients led to a higher COVID-19 mortality during a critical period during this past winter's surge.
Obesity and obstructive sleep apnea (OSA) tend to co-exist and are associated with a variety of cardiovascular risk factors, including inflammation, insulin resistance, abnormal cholesterol, and high blood pressure. While effective therapies are available for OSA, researchers are still unclear about what interventions are most effective in reducing the burden of risk factors for cardiovascular disease associated with OSA in obese patients.
Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs such as ibuprofen and naproxen.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason A Nitche, MD 457 Jack Martin Blvd, Brick, NJ 08724-7776 Ph: (732) 840-7500 | Dr Jason A Nitche, MD 457 Jack Martin Blvd, Brick, NJ 08724-7776 Ph: (732) 840-7500 |
News Archive
Lustgarten Foundation and Stand Up To Cancer, strategic partners in the Pancreatic Cancer Collective, offer comments on research published today in the journal Nature Medicine which describes a new therapeutic approach with promise for patients with pancreatic cancer.
A study led by scientists at the Institute for Research in Biomedicine and published in Nature Communications proposes chaperone protein Hps70 as an attractive therapeutic target for the treatment of Kennedy's disease—a rare neuromuscular condition—and of castration-resistant prostate cancer.
A new study from researchers at Johns Hopkins Bloomberg School of Public Health and colleagues suggests a slowdown in the use of convalescent plasma to treat hospitalized COVID-19 patients led to a higher COVID-19 mortality during a critical period during this past winter's surge.
Obesity and obstructive sleep apnea (OSA) tend to co-exist and are associated with a variety of cardiovascular risk factors, including inflammation, insulin resistance, abnormal cholesterol, and high blood pressure. While effective therapies are available for OSA, researchers are still unclear about what interventions are most effective in reducing the burden of risk factors for cardiovascular disease associated with OSA in obese patients.
Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs such as ibuprofen and naproxen.
› Verified 2 days ago
Theodore George Zaleski, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 212 Jack Martin Blvd, Suite D2, Brick, NJ 08724 Phone: 732-840-0446 Fax: 732-840-0491 | |
Il Hwan Kim, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 457 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-7500 Fax: 732-840-2088 | |
William A Law, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 457 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-7500 Fax: 732-840-2088 | |
Dr. Nader Mohamed Hebela, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 457 Jack Martin Blvd, Brielle Orthopedics, Brick, NJ 08724 Phone: 732-840-7500 | |
David J Rodricks, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 457 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-7500 Fax: 732-840-2088 | |
Brian Matthew Katt, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 457 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-7500 Fax: 732-840-2088 | |
Michael Nakashian, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 457 Jack Martin Blvd Ste 265, Brick, NJ 08724 Phone: 732-840-7500 |